Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILE THERAPEUTICS INCAGRX · Entity 87994 | Director | June 09, 2022 | June 10, 2022 |
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILE THERAPEUTICS INC
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,241 |
Reported balance
After 2022-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 670 · Balance 2,241 F1: These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F2: On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2032-06-08 | Direct | 807 |
Reported balance
After 2022-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-09 · Grant · Acquired 807 · Balance 807 F3: This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
F2: On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
F3: This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
Actinium Pharmaceuticals, Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,357 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Grant · Acquired 61,600 · Balance 62,357 F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-09-02 | Direct | 92,400 |
Reported balance
After 2026-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-02 · Grant · Acquired 92,400 · Balance 92,400 F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 92,400 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097744 · ownership.xml · derivative · entry 2 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,400 Underlying: Common Stock · 92,400 shares Expires 2036-09-02 F2 · derivative.exercise_date: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 21:00 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantCommon Stock | 61,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097744 · ownership.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,357 F1 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,311 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028227 · ownership.xml · derivative · entry 7 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,311 shares Expires 2033-12-28 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 72,156 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028227 · ownership.xml · derivative · entry 6 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,156 shares Expires 2032-07-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,351 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-25-028227 · ownership.xml · derivative · entry 5 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,351 shares Expires 2031-09-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-25-028227 · ownership.xml · derivative · entry 4 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires 2030-08-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuertock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $6.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028227 · ownership.xml · derivative · entry 3 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires 2029-07-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $23.49 | $0.00 |
DisclosureSEC source: 0001213900-25-028227 · ownership.xml · derivative · entry 2 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2028-07-13 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $47.40 | $0.00 |
DisclosureSEC source: 0001213900-25-028227 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2027-03-28 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 17:18 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 70,311 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-23-100068 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,311 Underlying: Common Stock · 70,311 shares Expires 2033-12-28 F1 · derivative.exercise_price: This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 19:14 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 72,156 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-22-036871 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,156 Underlying: Common Stock · 72,156 shares Expires 2032-07-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:46 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 807 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001104659-22-070176 · tm2218213-3_4seq1.xml · derivative · entry 2 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807 Underlying: Common Stock · 807 shares Expires 2032-06-08 F3 · derivative.exercise_date: This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:46 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-070176 · tm2218213-3_4seq1.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241 F1 · shares: These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F2 · balance_after: On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 17:03 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 18,351 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-21-046685 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,351 Underlying: Common Stock · 18,351 shares Expires 2031-09-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 19:10 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 29,905 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001104659-21-079617 · tm2119345-2_4seq1.xml · derivative · entry 2 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,905 Underlying: Common Stock · 29,905 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option was granted on June 8, 2021 and vests in full on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 19:10 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 24,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-079617 · tm2119345-2_4seq1.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,852 F1 · shares: These shares represent restricted stock units that were granted on June 8, 2021, which will vest and be settled in common stock on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 17:03 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-20-022319 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2030-08-12 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:21 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,606 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001104659-20-072487 · a4.xml · derivative · entry 2 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,606 Underlying: Common Stock · 22,606 shares Expires 2030-06-08 F2 · derivative.exercise_date: The option was granted on June 9, 2020 and vests in full on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:21 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 13,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-072487 · a4.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,342 F1 · shares: These shares represent restricted stock units that were granted on June 9, 2020, which will vest and be settled in common stock on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 16:58 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 250,000 | $0.23 Strike: $0.23 | $58,000.00 |
DisclosureSEC source: 0001213900-19-012871 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 16:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-19-034558 · a4.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option was granted on June 6, 2019 and vests in full on June 6, 2020, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 17:10 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009314 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 17:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 17,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-039215 · a4.xml · derivative · entry 3 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 17:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 17,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-039215 · a4.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 17:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-18-039215 · a4.xml · derivative · entry 2 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-06 F2 · derivative.exercise_date: The option was granted on June 7, 2018 and vests in full on June 7, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 07:08 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon stock | 22,730 | $0.43 | $9,773.90 |
DisclosureSEC source: 0001213900-18-002433 · f4022818shetty_actiniumpharm.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,730 Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 7,000 | $3.75 | $26,250.00 |
DisclosureSEC source: 0001104659-17-039242 · a4.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 17:03 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantRestricted Stock Units · Derivative | 17,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-038461 · a4.xml · derivative · entry 2 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Underlying: Common Stock · 17,949 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 17:03 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001104659-17-038461 · a4.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option was granted on June 8, 2017 and vests in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.